Jill Durocher

Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation's Clinical Policies Committee

May 1st, 2019
Abortion, general
Winikoff, Beverly, Mark, A., Foster, M.A., Grossman, D., Prager, S.W., Reeves, M., Velásquez, C.V., Winikoff, B.

Contraception; May 1, 2019; Vol. 99(5):265-266; doi:

Early abortion continues to expand outside of traditional clinics, through telemedicine, self-managed medication abortion, or in smaller offices that do not specialize in obstetrical care. Consequently, requiring Rh testing and anti-D immunoglobulin as part of abortion care is becoming a barrier. As of early 2019, the Society of Family Planning [1], the American College of Obstetricians and Gynecologists [2], and the Society of Obstetricians and Gynecologists of Canada [3] recommend that all Rh D-negative women receive anti-D immunoglobulin after an induced abortion, regardless of gestational age or type of procedure.